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Abstract
Background: Our objective was to determine the survival and causes of death in a large and well-characterized
cohort of patients with giant cell arteritis (GCA).
Methods: This is a hospital-based, retrospective, observational cohort study including patients diagnosed with GCA
in Western Norway during 1972–2012. Patients were identified through computerized hospital records using the
International Classification of Diseases (ICD)-coding system. Medical records were reviewed. Patients were randomly
assigned population controls matched on age, sex, and geography from the Central Population Registry of Norway
(CPRN). Date and cause of death were obtained from the Norwegian Cause of Death Registry (NCoDR). The survival
was analyzed using Kaplan-Meier methods with the Gehan-Breslow test and the causes of death using cumulative
incidence and Cox models for competing risks.
Results: We identified 881 cases with a clinical diagnosis of GCA of which 792 fulfilled the American College of
Rheumatology (ACR) 1990 classification criteria. Among those fulfilling the ACR criteria, 528 were also biopsy-
verified. Cases were matched with 2577 population controls. A total of 490 (56%) GCA patients and 1517 (59%)
controls died during the study period. We found no difference in the overall survival of GCA patients compared to
controls, p = 0.413. The most frequent underlying causes of death in both groups were diseases of the circulatory
system followed by cancer. GCA patients had increased risk of dying of circulatory disease (HR 1.31, 95% CI 1.13–
1.51, p < 0.001) but lower risk of dying of cancer (HR 0.56, 95% CI 0.42–0.73, p < 0.001) compared to population
controls.
Conclusions: We found no difference in the overall survival of GCA patients compared to matched controls, but
there were differences in the distribution of underlying death causes.
Keywords: Vasculitis, Giant cell arteritis, Temporal arteritis, Survival, Mortality, Causes of death, Epidemiology
Background
Giant cell arteritis (GCA) is the most common systemic
vasculitis in adults and may present as a relapsing inflam-
matory disease of the elderly [1, 2]. Neither pathogenesis
nor etiology of GCA is fully understood, although much
has been learned in recent years [3, 4]. Patients with GCA
risk a number of disease-related complications including
blindness and aortic aneurysms, yet therapeutic options
are limited [2]. The current cornerstone of GCA
treatment, glucocorticoids, has serious adverse effects, and
the newer treatments, such as interleukin (IL)-6 antagon-
ism, have so far unclear long-term safety [5–8]. The po-
tential for decreased survival of GCA patients has been
recognized, but very few robust epidemiological studies
have investigated this. A systematic review and meta-
analysis published in 2017 reported no difference in the
long-term mortality of GCA patients at a population level,
but increased mortality in hospital-based cohorts, particu-
larly in the years immediately after GCA diagnosis [9]. A
subsequent meta-analysis reported no difference in all-
cause mortality, but a significantly increased risk of death
due to cardiovascular disease (CVD) [10]. However, there
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was substantial heterogeneity among underlying studies,
and most individual studies were limited by small sample
sizes, possible misclassification bias, lack of well-matched
control cohorts, and/or short periods of follow-up [8, 11–
27]. We report a 41-year follow-up study of 881 clinically
diagnosed GCA patients whose disease characteristics
have been thoroughly verified. Patient outcomes were
compared to those of a large cohort of matched popula-
tion controls. Separate results for the subset of patients
fulfilling the American College of Rheumatology (ACR)
1990 criteria and the subset of biopsy-verified cases are
presented to optimize comparison with earlier reports.
Thus, this study aims to clarify the survivorship following
GCA diagnosis as well as the cause-specific mortality in
GCA patients.
Materials and methods
This is a retrospective cohort study including patients
diagnosed with GCA in Bergen Health Area during
1972–2012. Our material represents a predominantly
Caucasian referral cohort recruited from the three som-
atic hospitals in Bergen health area: Haukeland Univer-
sity Hospital, Haraldsplass Deaconess Hospital, and Voss
Hospital. These hospitals provide specialist healthcare
services to approximately 440,000 inhabitants in Horda-
land county, a mixed rural and urban area in Western
Norway [28]. Patients were identified through computer-
ized hospital records using the International Classifica-
tion of Diseases (ICD)-coding system. We collected data
by reviewing medical records of all patients registered
with the diagnosis of GCA following an outpatient visit
or admission to any ward in one of the study hospitals
between 1 January 1972 and 31 December 2012 (41-year
period). Further details about the patient inclusion
process have been published previously [29]. Every Nor-
wegian is given a unique 11-digit identification number
at birth or time of immigration, and patients were
matched for age (date of birth ± 1month), sex, and
county of residence to 3 control subjects randomly se-
lected from the Central Population Registry of Norway
(CPRN). The controls were required to be alive at the
time of GCA diagnosis for their matched case, and this
date was defined as the start of the observation period
for the control. The observation period ended when the
patient died or when the study ended (31 December
2012). We excluded duplicate control subjects and con-
trol subjects which were also among the cases. Extensive
demographic and clinical data were collected for the
cases, but for population controls, we had no available
information on potential risk factors, comorbid condi-
tions, or other clinical data. Data on the registered
deaths were obtained from the Norwegian Cause of
Death Registry (NCoDR) to which the death of every
Norwegian is mandatorily reported. NCoDR also
receives information on the date of death, but not always
the specific cause of death, of Norwegians whom have
emigrated. ICD-based NCoDR records are electronically
available from 1951, using ICD-8 in 1969–1985, ICD-9
in 1986–1995, and ICD-10 from 1996 until today. Death
causes in NCoDR were coded manually until 2005 when
the Automated Classification of Medical Entities
(ACME) system was introduced [30]. ACME is an auto-
mated coding system, which selects the underlying cause
of death according to internationally adopted rules. The
underlying cause of death (UCOD) refers to the disease
or injury that initiated the train of morbid events leading
directly to death. In contrast, a contributory cause of
death (CCOD) is a significant condition that unfavorably
influences the course of the morbid process and thus
contributes to the fatal outcome, but does not directly
cause death [31]. The registration of deaths in NCoDR
was complete for the entire study period. Variables re-
ceived from the NCoDR included the date of death and
ICD codes of the underlying and contributory causes of
death. Diagnoses were grouped according to the Euro-
pean Shortlist for Causes of Death 2012 version (COD-
SL-2012), which categorizes death causes into disease
groups and allows comparison of disease codes used in
ICD versions 8 thru 10.
Statistical analysis
Descriptive statistics were used to characterize the sample.
The t test was used for comparing continuous variables
and the chi-square or Fisher’s exact test for comparing
categorical variables. The overall cumulative survival in
cases and controls was estimated using Kaplan-Meier
plots with registered death as the event (outcome). Cumu-
lative survival was compared using the Gehan-Breslow
test. Follow-up time was estimated using the reverse
Kaplan-Meier method. The risks of death due to specific
causes (circulatory disease, cancer, infection, or “other”)
were analyzed using Cox proportional hazard (PH) models
based on cumulative incidence for competing risks. The
significance level was set to 0.05. The computing was
done using the Statistical Package for the Social Sciences
(SPSS) software version 24 (IBM Corp, Armonk) and R
software version 3.5 [32]. The graphics were created using
Matlab 9.0 (Mathworks Inc., Natick).
Results
Case identification
We identified 881 patients (71% female, mean age 73.0
(SD 8.6) years) with a clinical diagnosis of GCA, of
which 792 fulfilled the ACR 1990 classification criteria
for GCA. Among those fulfilling the ACR criteria, 528
were also biopsy-verified based on positive temporal ar-
tery biopsy (TAB). Among the 89 patients with a clinical
GCA diagnosis not fulfilling the ACR 1990 criteria, 53
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(60%) could be classified as having GCA according to
the expansion of the 1990 ACR criteria for GCA pro-
posed by Dejaco et al., though these criteria have not yet
been validated [33]. For the remaining 25 patients, the
clinical GCA diagnosis was in agreement with the opin-
ion of the study rheumatologist following a thorough
chart review, and 11 of these were also biopsy-verified.
Further details about the patient selection process have
been published previously [29]. The CPRN performed
the random selection of population controls matched to
cases by age, sex, and county of residence. One patient
lacked a Norwegian personal identification number and
could not be allocated matched controls. The other 880
cases were each matched with 3 population controls.
We excluded 26 randomly selected controls that were
also among the cases and 37 individuals who were ran-
domly selected as controls for more than one case. Thus,
the final cohort of population controls consisted of 2577
individuals (of which 2314 were matched to the 792 pa-
tients fulfilling ACR 1990 criteria and 1584 were
matched to biopsy-verified GCA patients). Two individ-
uals (both cases) had emigrated from Norway prior to
death. NCoDR had information on the date of death but
not the cause of death for these individuals. They are in-
cluded in the survival analysis but excluded from the
cause-specific analyses. Core characteristics of the in-
cluded cases and controls are presented in Table 1.
Overall survival
At the end of the study (31 December 2012), a total of
490 (69.6% female) GCA patients and 1517 (67.8% fe-
male) population controls were registered dead in
NCoDR (Table 1). Mean age at death was 83.6 (SD 7.5)
years for cases and 84.7 (SD 7.5) years for controls. Five
years after disease onset, more than 80% of GCA
patients were still alive, and at 10 years, approximately
50% were alive (Fig. 1). We found no significant differ-
ence in the overall cumulative survival or survival at any
specific time point after diagnosis, for any subgroup of
GCA patients compared to population controls (Fig. 1).
Follow-up times ranged from 0 to 35 years with a me-
dian follow-up time of 8 years for cases and 7 years for
controls (Table 1). Key features of our study compared
to previous reports evaluating the survival of GCA co-
horts are presented in Table 2.
Cause-specific risk of death
The most frequent UCODs in both GCA patients and
matched controls were diseases of the circulatory system
followed by cancer (Figs. 2 and 3). Combined, these dis-
eases accounted for approximately two thirds of all
deaths in both groups. The distribution differed between
GCA patients and matched controls, with GCA patients
having an increased risk of death due to circulatory dis-
ease (HR 1.31, 95% CI 1.13–1.51, p < 0.001) and infec-
tions (HR 2.34, 95% CI 1.15–4.80, p < 0.020) while
having a lower risk of cancer deaths (HR 0.56, 95% CI
0.42–0.73, p < 0.001). As shown in Table 3, we observed
the same for the ACR 1990 and biopsy-proven sub-
groups but with weaker, partially non-significant effects.
We note that GCA itself was listed as UCOD or CCOD
in very few patients despite a verified diagnosis of GCA
(twice as UCOD and 10 times as CCOD, i.e., 0.4% and
2.0% of all registered deaths respectively). All underlying
causes of death for cases and controls, grouped accord-
ing to COD-SL-2012, are illustrated in Fig. 3.
Circulatory diseases as the underlying cause of death
Among the 263 patients with circulatory disease as
UCOD, 110 died of ischemic heart disease, 50 of other
Table 1 Core characteristics of cases and controls
Clinical diagnosis ACR 1990 criteria fulfilled Biopsy-positive
Cases Controls Cases Controls Cases Controls
N = 881 N = 2577 N = 792 N = 2314 N = 528 N = 1584
Age at onset1 73 (8.6) 73 (8.6) 73.1 (8.5) 73.1 (8.5) 73.5 (7.9) 73.5 (7.9)
Female2 626 (71.1) 1823 (70.7) 566 (71.5) 1647 (71.2) 378 (71.6) 1134 (71.6)
Urban2 538 (61.1) 1360 (52.8) 484 (61.1) 1216 (52.5) 329 (62.3) 839 (53.0)
Biopsy-positive2 537 (61.0) – 528 (66.7) – 528 (100) –
Median observation time3 8 [3, 14] 7 [3, 12] 8 [3, 14] 7 [3, 11] 6 [3, 13] 9 [6, 13]
Number of deaths during observation2 490 (55.6) 1517 (58.9) 432 (54.5) 1335 (57.7) 292 (55.3) 952 (60.1)
Age at death1 83.6 (7.5) 84.7 (7.5) 83.8 (7.4) 84.6 (7.6) 83.8 (6.9) 84.7 (7.4)
Time to death4 12 (11, 13) 12 (11, 12) 12 (11, 13) 12 (11, 12) 12 (11, 13) 12 (11, 12)
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heart diseases, 58 of circulatory brain disease, and 45 of
“other” circulatory diseases. Corresponding figures for
controls were 655 deaths due to circulatory diseases, 308
deaths due to ischemic heart disease, 151 due to other
heart diseases, 143 due to circulatory brain disease, and
53 due to other circulatory diseases. The COD-SL-2012
category “other circulatory disease” includes aneurysms
and dissections, which are potential large vessel (LV)
complications of GCA. However, the category “other cir-
culatory disease” also includes embolism and throm-
bosis, rheumatic heart diseases, hypo- and hypertensive
diseases, atherosclerosis, and pulmonary heart diseases,
as well as other and unspecified disorders of the circula-
tory system. The numbers of registered deaths attributed
to each of these diagnoses were small and our study
lacked sufficient power to analyze the risk of these diag-
noses separately.
Discussion
In this study of 881 Norwegian GCA patients followed
over a 41-year period, we found no difference in the
overall survival of GCA patients compared to 2577 age-,
sex-, and geographically matched controls. This is in
agreement with several previous studies and supports
the notion that a diagnosis of GCA does not negatively
impact patients’ long-term survival [9, 10, 12, 13, 17–19,
21–23, 25–27, 34]. However, few previous reports have
comprehensively described long-term competing risks of
death in GCA patients. The results of our study indicate
that GCA patients have an increased risk of death due
to circulatory diseases and infections, but a decreased
risk of death due to cancer over time. Below, we discuss
factors that should further the understanding of the
current evidence on survival and cause-specific mortality
following GCA diagnosis.
Several factors may contribute to our finding of an equal
long-term survival in GCA patients compared to that of
population controls. Being monitored for a chronic dis-
ease such as GCA may represent a surveillance bias, in
which concomitant diseases may be detected and treated
earlier than they otherwise would have been. Also, it is
possible that our included cases represent a subset of pa-
tients with more benign disease, in particular as large
vessel (LV)-GCA may be underrepresented. Cases of LV-
GCA may have been misdiagnosed or undiagnosed in the
time period of our study, and their higher risk of mortality
was therefore not captured by our study [38]. Specifically,
there remains a gap in current knowledge concerning po-
tential differences in the prognosis for cranial versus cra-
nial plus LV manifestations. Despite increasing awareness
of possible LV involvement, LV imaging is still often re-
served for patients who present with large artery manifes-
tations, rather than being used routinely in the evaluation
of all patients diagnosed with GCA [2, 39]. Furthermore,
the awareness of the true scope of LV manifestations is
relatively recent. Therefore, published studies designed to
analyze differences between LV and cranial subsets of
GCA have had rather short periods of follow-up and thus
decreased potential to detect differences in late-occurring
outcomes such as death. Muratore et al. reported the hith-
erto largest study comparing patients with LV-GCA to
those with cranial disease [40]. They included 120 patients
with LV-GCA (defined by radiographic evidence of sub-
clavian artery vasculitis) and 212 patients with cranial
GCA (biopsy-positive) diagnosed between 1999 and 2008
and found that LV-GCA patients had higher relapse rate,
greater corticosteroid requirements, and increased preva-
lence of aortic aneurysms. However, Muratore et al. did
not compare differences in overall or cause-specific mor-
tality. A recent publication by Macchioni et al. reported
that large vessel involvement at diagnosis was associated
with reduced survival (multivariate HR 5.14, 95% CI 1.34–
19.74) in their retrospective Italian cohort, though ac-
knowledging that inclusion of only TAB-positive patients
Fig. 1 Kaplan-Meier survival plots for patients with GCA compared to matched controls
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Fig. 2 Kaplan-Meier plots for competing risks of death
Fig. 3 The distribution of underlying death causes in GCA patients and matched controls in Bergen Health Area 1972–2012 (all values represent the
number (%) of persons with the registered death cause). Underlying death causes are grouped according to COD-SL-2012: infections—COD-SL-2012
codes 1.1–1.4; cancer—COD-SL-2012 codes 2.1.1–2.1.22; diabetes—COD-SL-2012 code 4.1; dementia/Alzheimer’s—COD-SL-2012 codes 5.1 and 6.2;
circulatory disease—COD-SL-2012 codes 7.1–7.4; respiratory disease (including influenza and pneumonia)—COD-SL-2012 codes 8.1–8.4; ulcer—COD-SL-
2012 code 9.1; musculoskeletal—COD-SL-2012 code 11; other—all other COD-SL-2012 codes. GCA, giant cell arteritis; COD-SL-2012, European Shortlist for
Causes of Death (2012 version)
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in their study excluded patients with purely extracranial
GCA from their analyses [41].
Misclassification and selection bias
There is much heterogeneity among studies on GCA
epidemiology, which calls for careful considerations
when comparing results from different studies. Firstly, in
the studies with a large sample size but unvalidated
GCA diagnoses, there is a possibility of misclassification
bias [13, 14]. In the inclusion process for our study, 35%
of the initially selected patients coded as GCA were ex-
cluded to ensure a cohort of correctly diagnosed GCA
[29]. Thus, studies of cohorts lacking validation of diag-
nosis may include a large number of misdiagnosed per-
sons. Selection bias is another concern. We identified
only two prospective survival studies and both con-
cluded with no difference in overall mortality, but sam-
ple sizes were small, 64 and 46, and the inclusion
criteria differed [17, 22]. In studies of later years, inclu-
sion criteria have mainly been the fulfillment of ACR
1990 criteria for GCA or biopsy-proven cases only. Both
of these approaches have limitations. Restriction to
biopsy-proven cases has predominantly relied on TAB
results and thus limited case selection to patients with
cranial arteritis. Patients with LV involvement are less
likely to have temporal artery abnormalities according to
Muratore et al. who found that ACR classification cri-
teria for GCA were satisfied in only 39% of LV-GCA pa-
tients compared to 95% of GCA patients with cranial
arteritis (p < 0.001) [40]. The inclusion of only TAB-
positive patients thus excludes a majority of LV-GCA
patients. The ACR 1990 criteria are similarly flawed by
the lack of incorporating modern imaging evidence of
LV manifestations and by the narrow spectrum of clin-
ical (mostly cranial) features included in the criteria [42,
43]. To minimize potential ascertainment bias in our
study, we included patients given the diagnosis of GCA
on clinical grounds. To allow for this, we thoroughly
reviewed the medical records and we performed sub-
group analyses restricted to ACR 1990 and biopsy-
proven cases only to allow for comparison to other
studies. Unfortunately, for the time period of our study,
appropriate imaging tests for detection of LV-GCA
would not have been performed in the majority of cases.
A lack of complete capture of patients with LV-GCA is
therefore a probable limitation of ours as well as most
other hitherto published studies on GCA survival.
In the study by Aouba et al., only cases for which
GCA was listed as an underlying or non-underlying
cause of death in the death certificate were included
[13]. We found that only 2.4% of those who died in our
GCA cohort had GCA recorded as UCOD or CCOD on
their death certificate. Thus, Aouba and colleagues have
presumably not captured all GCA cases in their data-
base, but the included cases may nevertheless be a repre-
sentative sample. Their analysis of cause-specific death
patterns yielded similar results to that of our study, find-
ing an increased cardiovascular death risk but a de-
creased risk of death due to cancer.
Timing of death after diagnosis
The first study to compare the survival of GCA patients
to that of matched controls was published in 2009 [15].
The authors found an excess mortality in GCA patients at
5 years after GCA diagnosis, but also that the survival
rates for cases and controls converged after approximately
11 years. Some other studies have reported similar find-
ings [14, 36]. Baslund et al. analyzed death and causes of
death in three time periods: 0–2, 2–10 and > 10 years after
GCA diagnosis [35]. They argued that this subdivision re-
flects the clinical course of GCA, usually remitting within
6–24months of disease onset but with a possibility of late
involvement of the large vessels. Baslund and colleagues
found an increased risk of death due to circulatory dis-
eases during 0–2 years and > 10 years after the diagnosis
of GCA. Increased vascular risk associated with GCA has
also been reported by others and includes cardiovascular
disease, thromboembolic disease, and LV complications
[10, 13, 16, 21, 44, 45]. However, the underlying mecha-
nisms of all the vascular risks are not entirely understood
and may encompass both disease-related and treatment-
related causes [46]. The possibility of incomplete capture
of deaths due to late vascular complications is a limitation
of every study with a short follow-up period. In contrast,
the very long follow-up period in our study reduces the
Table 3 Cause-specific hazard ratios for the competing risks
of death
Events HR CI Lower CI upper p value
All cases, N = 3458
CVD 918 1.31 1.13 1.51 0.0003
Cancer 393 0.56 0.42 0.73 0.0000
Infections 31 2.34 1.15 4.80 0.0197
Other 665 1.03 0.86 1.23 0.7770
ACR 1990 criteria fulfilled, N = 3106
CVD 813 1.25 1.07 1.45 0.0047
Cancer 341 0.54 0.40 0.73 0.0001
Infections 28 2.03 0.95 4.34 0.0683
Other 585 1.04 0.86 1.26 0.6628
Biopsy-positive, N = 2112
CVD 576 1.26 1.05 1.51 0.0140
Cancer 234 0.54 0.37 0.78 0.0010
Infections 24 1.94 0.85 4.44 0.1173
Other 410 0.98 0.78 1.24 0.8629
CI confidence interval, CVD cardiovascular disease, HR hazard ratio
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risk of missing late-occurring complications and dimin-
ishes the risk of an erroneous conclusion based on varia-
tions through time.
Large vessel (LV) complications
LV complications were not a common cause of death in
our GCA cohort. There were few registered deaths due
to aortic aneurysm or dissection, and our study lacked
sufficient power to analyze the risk of these diagnoses
separately. Without autopsy data, there is a risk that
deaths due to vascular complications might have been
misclassified as caused by other (circulatory) disease. A
large autopsy study by Östberg in 1971 found the preva-
lence of GCA to be higher than indicated by the clinical
incidence and suggested that many cases remain clinic-
ally undiagnosed. Published reports indicate that GCA
patients with LV manifestations have increased risk of
death compared to GCA patients without LV manifesta-
tions and also compared to control individuals [37, 38].
Increasing use of modern imaging techniques allowing
visualization of large vessels may improve the prognosis
for these patients.
Strengths and weaknesses
Our data are limited by the retrospective design and lack
of data (for controls) on important risk factors such as
smoking, use of medications, co-morbidities, and other
potential confounders. We note that our cohort consists
of cases with predominantly cranial GCA (> 60% with
positive TAB). Thus, our results may not be representa-
tive for cases with purely extracranial GCA. A major
strength is the well-defined cohort of GCA cases in our
study resulting from a thorough review of clinical data,
excluding misclassified cases, and including hospitalized
patients as well as those only treated in outpatient
clinics. The study also included a large cohort of popula-
tion controls that were tightly matched with regard to
the most significant of all risk factors for death—age.
Access to national registries with mandatory reporting
provided excellent completeness of data concerning
dates and causes of deaths with virtually no loss to
follow-up. The large sample size of both cases and con-
trols rendered a well-powered analysis allowing us to de-
tect relevant differences between the groups. Finally, the
long inclusion period reduced the risk of evaluating ran-
dom time variations, and the long follow-up period se-
cured the inclusion of deaths due to late complications.
Conclusions
Based on our findings, the long-term survival of GCA
patients is comparable to that of population controls.
The most frequent underlying causes of death in both
GCA cases and controls were diseases of the circulatory
system followed by cancer. However, GCA patients had
increased risk of death due to circulatory diseases com-
pared to controls. This should be emphasized in the
management of patients with GCA, and contributing
risk factors for circulatory death need to be further deci-
phered and appropriately targeted. We stress that our
results may have limited transferability to patients with
mainly extracranial disease. Improved understanding of
the different subsets of GCA, specifically with or without
LV involvement, and appropriate tailoring of treatment
according to this, may alter the long-term outcomes for
GCA also on a group level.
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